Medical devices, healthcare technology and the business of care
PMA approval · N12159

SURGICEL BRAND ABSORBABLE HEMOSTAT

ETHICON, Inc. · Decision date Oct 14, 1960

FDA DECISIONN12159

What did the FDA approve?

FDA records N12159 as an original PMA application. The recorded decision is approval, dated Oct 14, 1960.

An approval order statement is not included in the imported record. Open the FDA listing for the decision documents.

Regulatory pathway
Original PMA
Clinical specialty
General, Plastic Surgery
Decision date
Oct 14, 1960

FDA source record

Regulatory record facts

Identifier
N12159
Regulatory pathway
Premarket approval application
Applicant
ETHICON, Inc.
Product code
LMG
Decision code
APPR
Decision date
Oct 14, 1960
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Agent, absorbable hemostatic, non-collagen based.

Applicant
ETHICON, Inc.
Product code
LMG
FDA device class
3

FDA decision timeline

  1. N12159 received

    Application receipt date recorded by FDA.

  2. N12159 · FDA decision

    APPR

Related devices and submissions

Explore the linked device profile

Other records with product code LMG

Product / regulatory recordCompanyPathwayDecision dateSource
Baxter Healthcare CorporationPMA supplementNov 7, 2026FDA
ETHICON, Inc.PMA supplementNov 5, 2026FDA
Baxter Healthcare CorporationPMA approvalMay 19, 2023FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

ETHICON, Inc.

Headquarters
Not reported
Brand website
ethicon.com
FDA applicant address
1000 Rte. 202, Raritan, NJ, 08869

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records